Coleman N - Search Results

1

Targeting un-MET needs in advanced non-small cell lung cancer.

Coleman N, Harbery A, Heuss S, Vivanco I, Popat S. Coleman N, et al. Lung Cancer. 2022 Feb;164:56-68. doi: 10.1016/j.lungcan.2021.12.016. Epub 2021 Dec 29. Lung Cancer. 2022. PMID: 35033939 Review.

2

Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib.

Coleman N, Wotherspoon A, Yousaf N, Popat S. Coleman N, et al. Lung Cancer. 2019 Aug;134:117-120. doi: 10.1016/j.lungcan.2019.05.025. Epub 2019 Jun 6. Lung Cancer. 2019. PMID: 31319969

3

Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.

Coleman N, Yousaf N, Arkenau HT, Welsh L, Popat S. Coleman N, et al. J Thorac Oncol. 2020 Aug;15(8):e142-e144. doi: 10.1016/j.jtho.2019.12.115. J Thorac Oncol. 2020. PMID: 32718541 Free article. No abstract available.

4

EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib.

Coleman N, Woolf D, Welsh L, McDonald F, MacMahon S, Yousaf N, Popat S. Coleman N, et al. J Thorac Oncol. 2020 Oct;15(10):e162-e165. doi: 10.1016/j.jtho.2020.05.006. J Thorac Oncol. 2020. PMID: 32981603 Free article. No abstract available.

5

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.

Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA. Coleman N, et al. Pharmgenomics Pers Med. 2021 Nov 25;14:1517-1535. doi: 10.2147/PGPM.S305068. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 34858045 Free PMC article. Review.

6

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.

Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Le X, et al. Among authors: coleman n. JCO Precis Oncol. 2021 Dec 13;5:PO.21.00135. doi: 10.1200/PO.21.00135. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34957368 Free PMC article.

7

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response.

Coleman N, Zhang B, Byers LA, Yap TA. Coleman N, et al. Br J Cancer. 2021 Mar;124(5):857-859. doi: 10.1038/s41416-020-01202-y. Epub 2020 Dec 16. Br J Cancer. 2021. PMID: 33328609 Free PMC article.

8

Taking Aim at the Undruggable.

Coleman N, Rodon J. Coleman N, et al. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-8. doi: 10.1200/EDBK_325885. Am Soc Clin Oncol Educ Book. 2021. PMID: 33989024 Free article.

9

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.

Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, Hong L, Park E, Balsara B, Leoni M, Pickering C, Myers J, Heymach J, Albacker LA, Hong D, Gillison M, Le X. Coleman N, et al. JCO Precis Oncol. 2023 Jan;7:e2200211. doi: 10.1200/PO.22.00211. JCO Precis Oncol. 2023. PMID: 36603172 Free PMC article.

10

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.

Coleman N, Ameratunga M, Lopez J. Coleman N, et al. Clin Med Insights Oncol. 2018 Feb 26;12:1179554918759079. doi: 10.1177/1179554918759079. eCollection 2018. Clin Med Insights Oncol. 2018. PMID: 29511362 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

665 results

Search Page

Filters